Table 3 Comparison of CD4+ T lymphocyte and CD8+ T lymphocyte rates of the clinical stages (n = 72)
Low Stage Median (Minimum-Maximum) | High Stage Median (Minimum-Maximum) | |||||
|---|---|---|---|---|---|---|
Control group (n = 29) | Study group (n = 19) | P value | Control group (n = 10) | Study group (n = 14) | P value | |
CD4 + T lymphocyte | ||||||
Intratumoral | 22 (0–87) | 14 (3–48) | 0.0291 | 26.5 (1–78) | 8.5 (2-220) | 0.266 |
Peritumoral | 157 (40–357) | 186 (27–378) | 0.238 | 179.5 (1-352) | 264.5 (22–405) | 0.458 |
P value | < 0.0001 | < 0.0001 | 0.0021 | < 0.0001 | ||
CD8 + T lymphocyte | ||||||
Intratumoral | 21 (4-180) | 18 (3–57) | 0.899 | 16.5 (9–42) | 15.5 (2-131) | 0.429 |
Peritumoral | 82 (18–360) | 98 (22–330) | 0.493 | 76.5 (20–245) | 192 (12–374) | 0.079 |
P value | < 0.0001 | 0.0002 | 0.0092 | 0.0003 | ||
CD4+/CD8+T ratio | ||||||
Intratumoral | 1.33 (0-7.13) | 0.57 (0.14–2.70) | 0.0154 | 1.47 (0.90–4.33) | 1.40 (0.11- | 0.564 |
Peritumoral | 82 (18–360) | 1.51 (0.18–3.85) | 0.598 | 1.58 (0.03–7.04) | 2.50) 1.24 (0.38–6.50) | 0.472 |
P value | 0.200 | 0.0001 | 0.276 | > 0.999 | ||